This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, Azstarys
by Zacks Equity Research
The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.
Aerie (AERI) Rises Despite Q4 Earnings Miss, Revenues Top Mark
by Zacks Equity Research
Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.
Esperion (ESPR) Q4 Earnings Miss, Coronavirus Woes Continue
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.
Tilray (KL) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Tilray (KL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for April 28th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 28th
Top Ranked Momentum Stocks to Buy for April 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th
Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment
by Zacks Equity Research
Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.
Company News For Jan 6, 2020
by Zacks Equity Research
Companies In The News Are: CANF, LW, INCY, NOVN
Company News For Dec 27, 2019
by Zacks Equity Research
Companies In The News Are: QGEN, IMMU, CANF, SBPH
All You Need to Know About Can-Fite (CANF) Rating Upgrade to Strong Buy
by Zacks Equity Research
Can-Fite (CANF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.